Article written by Pitt Street Research. For the full report click here:
Sensera Limited (ASX:SE1) designs, develops and manufactures Micro Devices (MEMS) for Medical and Industrial applications. Through recently acquired Nanotron, the company provides tracking solutions for the Agriculture, Mining and Healthcare verticals.The company’s MEMSbusiness is based in Boston (USA), while Nanotron is based in Germany.
Working with Harvard and VC-backed MedTech’s on newly emerging Organ-on-a-Chip technology
Sensera (ASX:SE1) announced a collaboration with Harvard University’s Wyss Institute for Biologically Inspired Engineering on the development of so-called Organ-on-a-Chip (OOC) technology. The collaboration has already resulted in four new development customers for SE1, through Harvard, most of which are backed by Venture Capital funds. Considering the amount of capital currently being invested in medical sensor technology, we believe this relatively new market can potentially start to generate very substantial revenues for SE1 in the next few years.
What is an Organ-on-a-Chip?
An OOC is a multi-channel 3-D microfluidic cell culture chip that simulates the activities, mechanics and physiological response of entire organs and organ systems. To date, researchers and MedTech companies have simulated the human heart, lung, kidney, artery, bone, cartilage and skin through early OOC applications.
Not only can OOC’s take over certain tasks inside a human body, thelonger-term potential is for OOC’s to shorten the time of new drug development and FDA approval, given that part of the traditional testing on animals can potentially be done with OOC’s rather than animals.
However, SE1 is not currently focusing on that aspect of the technology, but rather is working with venture-backed MedTech companies in the United States to bring to market OOC applications in the next few years.
Already revenue-generating, but the upside is in volume production
SE1 is already generating development revenues from four OOC collaborations in this field, but the financial upside is in volume production. As with other MedTech customers, SE1’s sales strategy in MedTech is aimed at the design-in of its technology into new products, resulting in future revenues once the end-products are starting to be mass-producedby the company’s customers.
A key aspect in bringing OOC’s to market will be SE1’s customers being able to develop the required product features for specific applications. In other words, even though SE1’s chips currently already function as theyshould, SE1’s customers will still need to get the overall end-product to work as required. The company is working with Harvard University and the OOC customers towards this end goal.
OOC market to go from non-existent in 2015 to US$ 170M in five years
The OOC market essentially didn’t exist three years ago. However, Allied Market Research anticipates that this market will grow to around US$ 170M by 2023. In our view, this is fairly conservative given the potential application areas and cost savings that may be achieved with OOC’s, e.g. in drug discovery.
Low-hanging fruit and longer-term potential
Key drivers of the OOC market include the application of OOC-enabled devices in the Healthcare industry and the increasing demand for OOC’s in drug discovery.
We believe the immediate opportunity for SE1 is in OOC-enabled devices through its current OOC development customers. Longer term, OOC’s hold the potential to revolutionize drug discovery. Worldwide pharmaceutical R&D totaled $141 billion in 2015, a large part of which is related to performing animal testing. We see substantial potential for cost savings by partly replacing animal testing by testing using OOC’s.
Boston-based Emulate, which is actually a spin out of Harvard’s Wyss Institute, is developingOOC’s to help model and predict effects of (new) drugs. The company has raised US$ 59M (~A$ 79M) in four years. Early adopters, or testers, of its technology include Johnson & Johnson, Merck and Seres Therapeutics.
Other emerging OOC players include Netherlands-based Mimetas (raised US$ 29M to date) and CN Bio Innovations.
Sales of disposable units makes revenues recurrent in nature
SE1’s OOC sensor modules range in price from a few hundred to a few thousand US dollars per unit. Once used, most OOC’s are disposed off, as opposed to other types of MEMS used in medical devices, e.g. implants. This recurrent element of OCC sales is highly attractive for SE1 and underlines the future revenue potential for the company.
For these reasons, we reiterate our Buy rating and A$ 0.50 price target for SE1.
SE1 reaffirmed its revenue guidance for FY19, i.e. 60% y-o-y growth compared to the projected US$ 6.25M to US$ 7.25M for FY18. As discussed in our previous update following the 3Q18 (March quarter) results, we believe the company is on track to achieve our US$ 11.2M revenue estimate for FY19.
We believe the OOC market, while small today, can contribute substantial revenues to SE1’s topline within a few years, i.e. several millions of dollars annually. Moreover, longer term growth is expected to be above 60% in the next five years. Given SE1’s strong position in this marketthrough its collaboration with Harvard, we expect the company may be able to capture substantial market share in OOC sensors during this period.
Please note, the usual disclaimers apply – click here
Pitt Street Research work is commissioned by the listed companies it covers, and Pitt Street Research has received or will receive payment for the preparation of such work. Please refer to the bottom of the research notes as published on Pitt Street Research’s web site for risks related to the companies being covered, as well our General Advice Warning, disclaimer and full disclosures. Also, please be aware that the investment opinion in this report is current as at the date of publication but that the circumstances of the company may change over time, which may in turn affect our investment opinion.